Other than ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit more than enough to tolerate FCR therapy, may still be good candidates for the latter, with the benefit remaining that this treatment is often completed in 6 months whilst ibrutinib must be taken indefinitely. This feature would be https://billk419iqz7.nizarblog.com/profile